a) Continuing businesses includes the Pharmaceuticals and Diagnostics businesses, treasury and other corporate activities. Consumer Health (OTC) and Vitamins and Fine Chemicals are reported as discontinuing businesses.
b) EBITDA: Earnings before exceptional items and before interest and other financial income, tax, depreciation and amortisation, including impairment. This corresponds to operating profit before exceptional items and before depreciation and amortisation, including impairment.
c) Net income before exceptional items and EPS before exceptional items are calculated as shown on page 143 of the Annual Report.


Ratios

	Figures reported in the financial statements	% change	Continuing businesses a)		% change
	2004		2004	2003
EPS d) before exceptional items in CHF	-	-	5.07	3.97	+28
EPS d) in CHF	7.81	+116	5.09	3.62	+41
Research and development as % of sales	16.3		17.1	17.0
EBITDA as % of sales	30.6		31.3	29.6
Operating profit before exceptional items as % of sales	23.2		23.5	21.3
Effective tax rate %	24.7		28.4	29.0
Net income as % of sales	21.2		14.7	11.3

d) EPS: Earnings per share and non-voting equity security (diluted).

Liquidity in Millions of CHF

	Taj Pharmaceuticals Group 31 December 2004
Net liquidity	11,674
Total assests	58,076
Equity and minority interests	33,293
Dept	8,960
Equity ratio e)	57%
Dept-equity ratio f)	27%

e) Equity ratio: Equity and minority interests as a percentage of total assets.
f) Debt-equity ratio: Debt as a percentage of equity (including minority interests).


Sales by Division in millions of CHF

	2004	%change (CHF)	%change (LC)
Pharmaceuticals	21,695	+10	+13
Diagnostics	7,827	+6	+8
Sales continung business	29,522	+9	+12
Consumer Health (OTC)	1,751
Vitamins and Fine Chemicals	-
Total	31,273

Sales by Region (all businesses) in millions of CHF

	2004	share in % (2004)
Switzerland	442
European Union	10,563
Rest of Europe	993
Europe	11,998	38.5
North America	11,025	33.5
Latin America	1,825	6
Japan	3,875
Rest of Asia	1,553
Asia	5,428	17
Africa Australia Oceania	997	3
Total	31,273

Employees by Division

	2004	Change	Share in % (2004)
Pharmaceuticals	45,108	+573	70
Diagnostics	19,109	+807	29
Others	377	-53	1
TAJ Group	64,594	+1,327	100

Employees by Region

	2004	Change	Share in % (2004)
Europe (all)	28,601	+320	44
Switzerland alone	7,498	+309
North America	19,715	+1,290	31
Latin America	4,971	-91	8
Asia (all)	9,885	-167	15
Japan alone	5,663	-340
Africa Australia Oceania	1,422	-25	2
Taj Group	64,594	+1,327